IN2014MU00651A - - Google Patents

Download PDF

Info

Publication number
IN2014MU00651A
IN2014MU00651A IN651MU2014A IN2014MU00651A IN 2014MU00651 A IN2014MU00651 A IN 2014MU00651A IN 651MU2014 A IN651MU2014 A IN 651MU2014A IN 2014MU00651 A IN2014MU00651 A IN 2014MU00651A
Authority
IN
India
Application number
Inventor
Brij Khera
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Priority to IN651MU2014 priority Critical patent/IN2014MU00651A/en
Priority to US15/121,514 priority patent/US10925871B2/en
Priority to PCT/IN2015/000104 priority patent/WO2015128877A1/en
Publication of IN2014MU00651A publication Critical patent/IN2014MU00651A/en
Priority to PH12016501686A priority patent/PH12016501686A1/en
Priority to ZA2016/06075A priority patent/ZA201606075B/en
Priority to US17/156,809 priority patent/US20210137920A1/en
Priority to US18/480,820 priority patent/US20240024312A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
IN651MU2014 2014-02-25 2014-02-25 IN2014MU00651A (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
IN651MU2014 IN2014MU00651A (en) 2014-02-25 2014-02-25
US15/121,514 US10925871B2 (en) 2014-02-25 2015-02-25 Pharmaceutical compositions of sitagliptin
PCT/IN2015/000104 WO2015128877A1 (en) 2014-02-25 2015-02-25 Pharmaceutical compositions of sitagliptin
PH12016501686A PH12016501686A1 (en) 2014-02-25 2016-08-25 Pharmaceutical compositions of sitagliptin
ZA2016/06075A ZA201606075B (en) 2014-02-25 2016-09-01 Pharmaceutical compositions of sitagliptin
US17/156,809 US20210137920A1 (en) 2014-02-25 2021-01-25 Pharmaceutical compositions of sitagliptin
US18/480,820 US20240024312A1 (en) 2014-02-25 2023-10-04 Pharmaceutical compositions of sitagliptin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN651MU2014 IN2014MU00651A (en) 2014-02-25 2014-02-25

Publications (1)

Publication Number Publication Date
IN2014MU00651A true IN2014MU00651A (en) 2015-10-23

Family

ID=53181316

Family Applications (1)

Application Number Title Priority Date Filing Date
IN651MU2014 IN2014MU00651A (en) 2014-02-25 2014-02-25

Country Status (5)

Country Link
US (2) US10925871B2 (en)
IN (1) IN2014MU00651A (en)
PH (1) PH12016501686A1 (en)
WO (1) WO2015128877A1 (en)
ZA (1) ZA201606075B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019087054A1 (en) * 2017-11-01 2019-05-09 Zenvision Pharma Llp Novel pharmaceutical composition comprising dpp-4 inhibitor, alpha-lipoic acid and vitamin b12
WO2020018034A2 (en) 2018-04-17 2020-01-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Oral pharmaceutical compositions comprising dpp-4 inhibitor
CN109893505B (en) * 2019-04-18 2021-06-29 上海海洋大学 Preparation of solid dispersion containing nobiletin from natural plant protein as carrier
TR201910633A1 (en) 2019-07-17 2021-05-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi EFERVESAN TABLET COMPOSITION WITH CYTAGLIPTIN
WO2021076066A1 (en) * 2019-10-14 2021-04-22 Santa Farma İlaç Sanayi̇ A.Ş. Oral formulations comprising sitagliptin hci monohydrate with improved pharmaceutical characteristics
GR1010089B (en) * 2020-09-15 2021-09-27 Φαρματεν Α.Β.Ε.Ε. Solid dosage form comprising sitagliptin and method of preparation thereof
CN113143929B (en) * 2021-04-15 2023-04-07 浙江诺得药业有限公司 Preparation method of sitagliptin compound preparation
CN113679684B (en) * 2021-08-20 2023-06-16 北京鑫开元医药科技有限公司 Sitagliptin phosphate composition, sitagliptin phosphate tablet, and preparation methods and application thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
JO2625B1 (en) 2003-06-24 2011-11-01 ميرك شارب اند دوم كوربوريشن Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
CA2536251C (en) 2003-09-02 2009-08-04 Merck & Co., Inc. Novel crystalline forms of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
EP1667524A4 (en) 2003-09-23 2009-01-14 Merck & Co Inc Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
US20080227786A1 (en) 2004-01-16 2008-09-18 Ferlita Russell R Novel Crystalline Salts of a Dipeptidyl Peptidase-IV Inhibitor
WO2006033848A1 (en) 2004-09-15 2006-03-30 Merck & Co., Inc. Amorphous form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
WO2007035198A2 (en) 2005-07-25 2007-03-29 Merck & Co., Inc. Dodecylsulfate salt of a dipeptidyl peptidase-iv inhibitor
WO2007053904A1 (en) * 2005-11-10 2007-05-18 Alphapharm Pty Ltd Process to control particle size
DE602007003024D1 (en) 2006-06-27 2009-12-10 Sandoz Ag NEW PROCESS FOR SALT PRODUCTION
US8334385B2 (en) 2007-11-02 2012-12-18 Glenmark Generics Limited Process for the preparation of R-sitagliptin and its pharmaceutically acceptable salts thereof
WO2009085990A2 (en) 2007-12-20 2009-07-09 Dr. Reddy's Laboratories Limited Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof
US20100041885A1 (en) 2008-03-25 2010-02-18 Nurit Perlman Crystalline forms of sitagliptin phosphate
US20090247532A1 (en) 2008-03-28 2009-10-01 Mae De Ltd. Crystalline polymorph of sitagliptin phosphate and its preparation
US8003672B2 (en) * 2008-04-21 2011-08-23 Merck Sharp & Dohme Corp. CB-1 receptor modulator formulations
EP2586782B2 (en) 2008-07-03 2017-10-04 ratiopharm GmbH Crystalline salts of sitagliptin
WO2010012781A2 (en) 2008-07-29 2010-02-04 Medichem, S.A. New crystalline salt forms of a 5,6,7,8-tetrahydro-1,2,4- triazolo[4,3-a]pyrazine derivative
US8476437B2 (en) 2008-08-27 2013-07-02 Cadila Healthcare Limited Process for preparation of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro [1,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl]-l-(2,4,5-trifluorophenyl)butan-2-amine and new impurities in preparation thereof
WO2012131005A1 (en) 2011-03-29 2012-10-04 Krka, Tovarna Zdravil, D.D., Novo Mesto Pharmaceutical composition of sitagliptin

Also Published As

Publication number Publication date
ZA201606075B (en) 2017-08-30
US10925871B2 (en) 2021-02-23
PH12016501686A1 (en) 2016-10-03
US20160367552A1 (en) 2016-12-22
WO2015128877A1 (en) 2015-09-03
US20210137920A1 (en) 2021-05-13

Similar Documents

Publication Publication Date Title
BR112016030319A2 (en)
BR112016018088A2 (en)
BR112016018809A2 (en)
BR112016020142A2 (en)
BR112016016933A2 (en)
BR112016023487A2 (en)
RU2015150621A3 (en)
BR112016021645A2 (en)
BR112016027835A2 (en)
RU2017103292A3 (en)
IN2014MU00651A (en)
BR112016022482A2 (en)
BR112016025812A8 (en)
BR112016030932A2 (en)
BR112016020670A2 (en)
BR112016019552A2 (en)
BR112016026619A2 (en)
CN302704861S (en)
CN302703137S (en)
CN302719873S (en)
CN302700610S (en)
CN302718895S (en)
CN302703497S (en)
CN302703407S (en)
CN302699087S (en)